Strong Sales Growth Above Market Expectations

Johnson and Johnson (J&J) has kicked off fiscal 2025 with impressive momentum, announcing a 2.4% increase in first-quarter sales, totaling $21.9 billion. This performance not only surpasses the figures from the same period last year but also exceeds market expectations, showcasing the company's robust health and potential for continued growth.

Earnings Per Share and Net Earnings Soar

The company's financial health is further highlighted by a staggering 238.8% year-over-year increase in diluted earnings per share, reaching $4.54. Net earnings followed suit, jumping 237.9% to $11 billion, underscoring J&J's strong operational efficiency and market position.

Leadership's Confidence in 2025 Outlook

"The power of Johnson & Johnson’s uniquely diversified portfolio was on full display this quarter, with strong operational sales growth reinforcing our confidence in 2025 guidance," stated Chairman and CEO Joaquin Duato. This optimism is mirrored in the stock's performance, which saw a 0.43% increase in premarket trading, reaching $155.03 per share.